The phase 2 trial aimed to investigate the antitumor activity and safety of lorlatinib in TKI naïve in patients with advanced ROS1-positive NSCLC. The primary endpoint was to determine ORR. Researchers noticed lorlatinib’s effectiveness and safety, supporting earlier treatment for ROS1-positive NSCLC. ROS1 rearrangement is rare but an attractive therapeutic target in advanced […]...
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Background Major histocompatibility complex class I (MHC-I) loss is frequent in non-small cell lung cancer (NSCLC) rendering tumor cells resistant to T cell lysis. NK cells kill MHC-I-deficient tumor cells, and although previous work indicated their …
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …
Background Adoptive cell transfer (ACT) shows promise as an immunotherapy for melanoma and other cancers. However, there are several challenges associated with ACT such as the logistical complexity and inconsistency when using patient-derived antigen-presenting cells for …
Background Immune checkpoint inhibitors (ICIs) are standard therapy for advanced hepatocellular carcinoma (HCC). However, the efficacy of combining nivolumab and ipilimumab in Anti-PD(L)-1 Naïve and Experienced HCC patients remains unclear. Methods We retrospectively reviewed 23 patients with advanced …
